Qlt Inc (QLTI): Broadfin Capital Adds Another 820,000 Shares to its Position

Page 7 of 10

Page 7 of 10 – SEC Filing
Item 7.
Material to be Filed as Exhibits.
An agreement relating to the filing of a joint statement as required by Rule 13d-1(f) under the Securities Exchange Act of 1934 is filed herewith as Exhibit A.
A description of the transactions in the shares of the Common Stock that were effected by the Reporting Persons during the last 60 days is filed herewith as Exhibit B.
A copy of the Voting Agreement, filed by the Issuer on June 17, 2016 as Exhibit 10.5 of the Form 425, and incorporated herein by reference.
For a complete description of the Merger Agreement see the Form 8-K filed by the Issuer on June 15, 2016 (which includes a copy of the Merger Agreement filed as exhibit 2.1 thereto).
A copy of the Consent of Kevin Kotler to serve as director, filed by the Issuer on September 12, 2016 as Exhibit 99.10 of the Form S-4, and incorporated herein by reference.

Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)

Page 7 of 10